CClinicalTrials.gg
Active, not recruitingNCT06407336Updated May 9, 2024

Comparative Effect of Cylindrical Lenses Verses Spherical Equilient on Contrast Sensitivity

An interventional study of Contrast sensitivity and Refraction in Low Vision Aids, sponsored by Superior University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-09.

Sponsored by Superior University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Oct 2023, registered May 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

the concept of spherical equivalent plays a pivotal role in simplifying the prescription and enhancing communication between eye care professionals and patients. The spherical equivalent is a calculated value that condenses the spherical and cylindrical components into a single power.

Read the detailed description

Mathematically, it is determined by adding half of the cylindrical power to the spherical power (SE = Sphere + (Cylinder/2)). This calculated value serves as a convenient representation of the overall refractive error, aiding in a more straightforward understanding of the prescription. Understanding their individual and collective impact on contrast sensitivity opens up new avenues for refining corrective interventions and enhancing the overall quality of vision. This article aims to demystify the intricate relationship between spherical equivalent and cylindrical correction, and their collective impact on contrast sensitivity.

02

Conditions studied

  • Low Vision Aids

Browse trials for

03

In context

Vision, Low

214 studies on the registry are indexed under Vision, Low; 41 are open to participants now.

This study's enrollment of 68 is above the median of 60 across 155 interventional studies indexed under Vision, Low.

Browse Vision, Low studies →

Lead sponsor

Superior University is the lead sponsor of 242 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients within 18 to 35 years will be included.
  • Both genders will be included.
  • Patients having astigmatism will be included.
  • Patients having 6/6 corrected vision will be included.
  • Eyes having no other ocular pathology will be included.
  • Patients having no history of ocular surgery or corneal scar will be included.

Exclusion criteria

Exclusion Criteria:

  • i. Eyes having any ocular pathology will be excluded.
  • Patients with corneal suture will be excluded.
  • Those using contact lenses instead of spectacles for vision correction will be excluded.
  • Participants with a history of eye surgery within the past year will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Contrast sensitivity

    Diagnostic Test: Contrast sensitivity

  • Other
    Refraction

    Other: Refraction

Interventions

  • Diagnostic testContrast sensitivity

    Contrast sensitivity will be assessed by using two different techniques of refraction on is Cylinderical lens and other is Spherical equivalent

  • OtherRefraction

    Refraction will be performed and contrast sensitivity will be assessed to assess patient comfort level and compliance.

06

What researchers measure

Primary outcomes

  1. Contrast sensitivity

    The ability to perceive sharp and clear outlines of very small objects. It is also defined as the ability to identify minute differences in the shadings and patterns. CS helps detect objects without a clear outline and distinguish them from their background contrast

    Time frame: 12 Months

07

Study locations

1 site
  • Sehat Medical Complex Hanjarwal
    Lahore, Punjab, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06407336
Lead sponsor
Superior University
Responsible party
Muhammad Naveed Babur (Principal Investigator, Superior University) — Principal investigator
First posted
May 9, 2024
Start date
Oct 1, 2023
Primary completion
Mar 1, 2024
Completion
Sep 1, 2024 (estimated)
Last update
May 9, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion